

Syphilis Serology 3, 2017

Thank you for participating in the third Syphilis serology round in the year 2017. There were 175 participants from seventeen countries.

Specimens

The round included two serum specimens without any preservative. The specimens were distributed to participants by mail without any temperature control. The instruction was to analyse the specimens as soon as possible, at latest within one week. The storage should have been in a refrigerator.

Specimen S001: LQ757817031 was representing an active syphilis infection.

Specimen S002: LQ757817032 was representing an active syphilis infection.

Results

In the LabScala report the accepted results are marked with green color and laboratory's own result with a black radio button. In the scoring section you can see summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodics counts in the tables. **Change in the report layout:** Please note that by default the distribution pies are closed in the scoring reports. You are able to open the distribution pies by clicking the screen button at the right end of the RESULT DISTRIBUTION row.

The cumulative scoring data is calculated according to the order of the results. Therefore we recommend you to locate the results of your primary method to the top of the result form. The guidance for interpretation of the results you can find in LabScala under the "Labscala user instructions"- button.

If you have no results you will get a note that you have not responded on time.

The participants of this EQA scheme were able to report three (3) results for each specimen in LabScala, when the material is sufficient for additional analysis. This opportunity is intended for different test kits or instruments of one testing unit.

In case you have any questions regarding the reports, please contact the EQA Coordinator.

Comments

Sample S001 had positive antibody titers in both non-treponemal and treponemal tests. Negative and weakly positive results were considered false in these tests.

92% of non-treponemal test results and all treponemal test results were correct.

Sample S002 had positive antibody titer in non-treponemal and high antibody titer in treponemal test. Negative and weakly positive results were considered false in these tests.
95% of non-treponemal test results and all treponemal test results were correct.

2017-11-07

FINAL REPORT

Items sent 2017-09-25
Round closed 2017-10-19
Results released 2017-11-07

Product no. 5880
LQ757817031-032/US

The report contains

-Individual tables for interpretation and laboratory specific scores

Request for corrections

Typing errors in laboratory's result forms are on laboratory's own responsibility. Labquality accepts responsibility only for result processing.

Requests must be notified by writing within three weeks from the date of this letter.

Expert

Dr. Tapio Seiskari, MD,
Fimlab Laboratories, Finland

Authorized by

EQA Coordinator
Satu Eklund
T. +358 9 8566 8249
satu.eklund@labquality.fi

Labquality
Kumpulantie 15
FI-00520 HELSINKI

Telephone
+358 9 8566 8200

Fax
+358 9 8566 8280
+358 9 8566 8281

info@labquality.fi
www.labquality.fi

© Labquality



Next page →

Scores

Note! In analyte TrpaAb the IgM-test results are not scored.

The round is scored based on test results and clinical interpretations. The test or interpretation will be scored if 60 % of the results are as expected. Following general rules are followed:

- Expected test result	2/2 points.
- Partly expected test result	1/2 points.
- Deviating test result	0/2 points.
- Expected clinical interpretation	4/4 points.
- Deviating clinical interpretation	0/4 points.

Laboratory's scores have been converted to percentage (own success rate, % from maximum scores) with a target at 100%. Own success rate is compared with the success rate of all results.

The reports of this round are available on **Labquality homepage** (www.labquality.fi). Please **Login to LabScala** and fill in your laboratory's **client code/personal user name** and **password**. Then please choose **My Documents** → **View Reports**.

End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.

